======= ANAPC11 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: ANAPC11
  * **<color #00a2e8>Official Name</color>**: anaphase promoting complex subunit 11
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=51529|51529]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q9NYG5|Q9NYG5]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=ANAPC11&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20ANAPC11|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/614534|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  Together with the cullin protein ANAPC2, constitutes the catalytic component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. May recruit the E2 ubiquitin-conjugating enzymes to the complex. {ECO:0000269|PubMed:11739784, ECO:0000269|PubMed:18485873}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|zf-Apc11|
|zf-rbx1|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|positive regulation of mitotic metaphase/anaphase transition|
|positive regulation of mitotic sister chromatid separation|
|positive regulation of metaphase/anaphase transition of cell cycle|
|positive regulation of chromosome separation|
|cullin-RING ubiquitin ligase complex|
|ubiquitin-ubiquitin ligase activity|
|positive regulation of mitotic sister chromatid segregation|
|cullin family protein binding|
|anaphase-promoting complex|
|positive regulation of chromosome segregation|
|protein K11-linked ubiquitination|
|regulation of mitotic metaphase/anaphase transition|
|positive regulation of mitotic nuclear division|
|regulation of metaphase/anaphase transition of cell cycle|
|regulation of mitotic sister chromatid separation|
|regulation of chromosome separation|
|positive regulation of nuclear division|
|regulation of mitotic sister chromatid segregation|
|positive regulation of mitotic cell cycle phase transition|
|regulation of sister chromatid segregation|
|anaphase-promoting complex-dependent catabolic process|
|positive regulation of cell cycle phase transition|
|regulation of chromosome segregation|
|positive regulation of mitotic cell cycle|
|regulation of mitotic nuclear division|
|positive regulation of chromosome organization|
|regulation of nuclear division|
|ubiquitin protein ligase activity|
|ubiquitin-protein transferase activity|
|positive regulation of cell cycle process|
|protein polyubiquitination|
|proteasome-mediated ubiquitin-dependent protein catabolic process|
|regulation of chromosome organization|
|proteasomal protein catabolic process|
|positive regulation of cell cycle|
|regulation of mitotic cell cycle phase transition|
|regulation of cell cycle phase transition|
|cell division|
|ubiquitin-dependent protein catabolic process|
|modification-dependent protein catabolic process|
|modification-dependent macromolecule catabolic process|
|proteolysis involved in cellular protein catabolic process|
|cellular protein catabolic process|
|positive regulation of organelle organization|
|regulation of mitotic cell cycle|
|protein catabolic process|
|mitotic cell cycle|
|protein ubiquitination|
|regulation of cell cycle process|
|protein modification by small protein conjugation|
|nucleolus|
|cellular macromolecule catabolic process|
|protein modification by small protein conjugation or removal|
|macromolecule catabolic process|
|organonitrogen compound catabolic process|
|regulation of cell cycle|
|positive regulation of cellular component organization|
|proteolysis|
|regulation of organelle organization|
|cell cycle|
|organic substance catabolic process|
|cellular catabolic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='default' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp525|Sulforaphane 9μM R08 exp525]]|-2.35|
|[[:results:exp489|Hippuristanol 0.12μM R08 exp489 no dilution day6]]|-2.21|
|[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|-2.11|
|[[:results:exp37|Wortmannin 0.5μM R00 exp37]]|-2.11|
|[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|-1.98|
|[[:results:exp277|Curcumin 6.5μM R06 exp277]]|-1.91|
|[[:results:exp447|Amiloride 100μM R08 exp447]]|-1.89|
|[[:results:exp414|Tozasertib 0.1μM R07 exp414]]|-1.89|
|[[:results:exp291|LLY-284 2.6μM R06 exp291]]|-1.88|
|[[:results:exp75|MK-1775 0.32μM R02 exp75]]|-1.86|
|[[:results:exp210|LB-100 2μM R05 exp210]]|-1.81|
|[[:results:exp289|Hydroxyurea 15μM R06 exp289]]|-1.79|
|[[:results:exp302|35°C R06 exp302]]|-1.74|
|[[:results:exp260|ABT-702 0.1μM R06 exp260]]|-1.73|
|[[:results:exp143|Phenformin 20μM R03 exp143]]|-1.73|
|[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|-1.73|
|[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|-1.71|
|[[:results:exp4|Actinomycin-D 0.01μM R00 exp4]]|1.89|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
No correlation found to any other genes in chemogenomics.
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 739/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|1/1|
|bile duct|28/28|
|blood|28/28|
|bone|26/26|
|breast|33/33|
|central nervous system|56/56|
|cervix|4/4|
|colorectal|17/17|
|esophagus|13/13|
|fibroblast|1/1|
|gastric|16/16|
|kidney|21/21|
|liver|20/20|
|lung|75/75|
|lymphocyte|16/16|
|ovary|26/26|
|pancreas|24/24|
|peripheral nervous system|16/16|
|plasma cell|15/15|
|prostate|1/1|
|skin|24/24|
|soft tissue|9/9|
|thyroid|2/2|
|upper aerodigestive|22/22|
|urinary tract|29/29|
|uterus|5/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 209
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 4.3 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='ANAPC11 Expression in NALM6 Cells: 4.3'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>